These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18398970)

  • 1. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
    Kiser JJ; Aquilante CL; Anderson PL; King TM; Carten ML; Fletcher CV
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):298-303. PubMed ID: 18398970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G; King JR; Acosta EP; Fletcher CV
    AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of active renal tubular efflux of tenofovir.
    Ray AS; Cihlar T; Robinson KL; Tong L; Vela JE; Fuller MD; Wieman LM; Eisenberg EJ; Rhodes GR
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3297-304. PubMed ID: 17005808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
    Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
    Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
    Neumanova Z; Cerveny L; Ceckova M; Staud F
    AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
    García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
    J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.
    Baheti G; Kiser JJ; Havens PL; Fletcher CV
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5294-9. PubMed ID: 21896913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
    Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
    Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
    Izzedine H; Hulot JS; Villard E; Goyenvalle C; Dominguez S; Ghosn J; Valantin MA; Lechat P; Deray AG
    J Infect Dis; 2006 Dec; 194(11):1481-91. PubMed ID: 17083032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
    Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
    Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.
    Moss JA; Malone AM; Smith TJ; Butkyavichene I; Cortez C; Gilman J; Kennedy S; Kopin E; Nguyen C; Sinha P; Hendry RM; Guenthner P; Holder A; Martin A; McNicholl J; Mitchell J; Pau CP; Srinivasan P; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.
    Moss DM; Kwan WS; Liptrott NJ; Smith DL; Siccardi M; Khoo SH; Back DJ; Owen A
    Antimicrob Agents Chemother; 2011 Feb; 55(2):879-87. PubMed ID: 21078936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.
    Chen J; Flexner C; Liberman RG; Skipper PL; Louissaint NA; Tannenbaum SR; Hendrix CW; Fuchs EJ
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):593-9. PubMed ID: 23187888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
    Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
    Nishijima T; Komatsu H; Higasa K; Takano M; Tsuchiya K; Hayashida T; Oka S; Gatanaga H
    Clin Infect Dis; 2012 Dec; 55(11):1558-67. PubMed ID: 22955427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
    Rodríguez-Nóvoa S; Labarga P; Soriano V; Egan D; Albalater M; Morello J; Cuenca L; González-Pardo G; Khoo S; Back D; Owen A
    Clin Infect Dis; 2009 Jun; 48(11):e108-16. PubMed ID: 19400747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.